keyword
MENU ▼
Read by QxMD icon Read
search

FIB-4

keyword
https://www.readbyqxmd.com/read/29161258/insulin-resistance-and-hyperandrogenism-drive-steatosis-and-fibrosis-risk-in-young-females-with-pcos
#1
Salvatore Petta, Alessandro Ciresi, Jessica Bianco, Vincenzo Geraci, Roberta Boemi, Luigi Galvano, Franco Magliozzo, Giovanni Merlino, Antonio Craxì, Carla Giordano
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) recognize obesity and insulin resistance (IR) as common pathogenic background. We assessed 1) whether PCOS is a risk factor for steatosis, and 2) the impact, in PCOS patients, of IR and hyperandrogenism on steatosis and fibrosis. METHODS: We considered 202 consecutive Italian PCOS nondiabetic patients and 101 age-matched controls. PCOS was diagnosed applying the Rotterdam diagnostic criteria...
2017: PloS One
https://www.readbyqxmd.com/read/29154965/noninvasive-assessment-of-nonalcoholic-fatty-liver-disease-clinical-prediction-rules-and-blood-based-biomarkers
#2
REVIEW
Eduardo Vilar-Gomez, Naga Chalasani
The correct identification of patients at increased risk of non-alcoholic steatohepatitis (NASH) and advanced fibrosis is a critical step in the assessment of NAFLD. Since liver biopsy is invasive, expensive and prone to sampling error, several clinical prediction rules and blood-based biomarkers have been developed as an attractive and affordable alternatives to guide clinicians to identify patients at high risk of NASH and advanced fibrosis. Current biomarkers constitute predictive models (e.g., NAFLD fibrosis score, FIB-4 index and BARD score) or direct measures of inflammation (e...
November 14, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29151696/value-of-gamma-glutamyltranspeptidase-to-platelet-ratio-in-diagnosis-of-hepatic-fibrosis-in-patients-with-chronic-hepatitis-b
#3
Yan-Chao Hu, Hao Liu, Xiao-Yan Liu, Li-Na Ma, Yu-Hua Guan, Xia Luo, Xiang-Chun Ding
AIM: To investigate the value of the gamma-glutamyltraspeptidase (GGT)-to-platelet (PLT) ratio (GPR) in the diagnosis of hepatic fibrosis in patients with chronic hepatitis B (CHB). METHODS: We included 390 untreated CHB patients in this study. The GPR, aspartate aminotransferase (AST)-to-PLT ratio index (APRI), and fibrosis-4 (FIB-4) of all patients were analysed to determine if these parameter were correlated with age, gender, medical history, liver function [total bilirubin (TBil), alanine aminotransferase (ALT), and AST], GGT, PLT count, or hepatic fibrosis stage...
November 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29150142/association-between-non-alcoholic-fatty-liver-disease-and-cancer-incidence-rate
#4
Gi-Ae Kim, Han Chu Lee, Jaewon Choe, Min-Ju Kim, Min Jung Lee, Hye-Sook Chang, In Young Bae, Hong-Kyu Kim, Jihyun An, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim
BACKGROUND & AIMS: Little is known about the association between non-alcoholic fatty liver disease (NAFLD) and cancer development. This study investigated the cancer incidence rates in NAFLD and analysed the association between NAFLD and cancer development. METHODS: This historical cohort study included subjects who were followed up for >1 year after having a heath checkup at a tertiary hospital in Korea from September 1, 2004 to December 31, 2005. NAFLD was diagnosed by ultrasonographic detection of hepatic steatosis in the absence of other known liver disease, including alcoholic or viral hepatitis...
November 2, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29147645/real-world-cure-rates-for-hepatitis-c-virus-treatments-that-include-simeprevir-and-or-sofosbuvir-are-comparable-to-clinical-trial-results
#5
Kian Bichoupan, Neeta Tandon, James F Crismale, Joshua Hartman, David Del Bello, Neal Patel, Sweta Chekuri, Alyson Harty, Michel Ng, Keith M Sigel, Meena B Bansal, Priya Grewal, Charissa Y Chang, Jennifer Leong, Gene Y Im, Lawrence U Liu, Joseph A Odin, Nancy Bach, Scott L Friedman, Thomas D Schiano, Ponni V Perumalswami, Douglas T Dieterich, Andrea D Branch
AIM: To assess the real-world effectiveness and cost of simeprevir (SMV), and/or sofosbuvir (SOF)-based therapy for chronic hepatitis C virus (HCV) infection. METHODS: The real-world performance of patients treated with SMV/SOF ± ribavirin (RBV), SOF/RBV, and SOF/RBV with pegylated-interferon (PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included...
November 12, 2017: World Journal of Virology
https://www.readbyqxmd.com/read/29128062/diagnosis-and-evaluation-of-nonalcoholic-fatty-liver-disease-nonalcoholic-steatohepatitis-including-noninvasive-biomarkers-and-transient-elastography
#6
REVIEW
Eugenia Tsai, Tai-Ping Lee
The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) are increasing and identification of people at risk of disease progression is extremely important. The current gold standard for diagnosing NAFLD/nonalcoholic steatohepatitis (NASH) is by liver biopsy, but it has several limitations. Noninvasive tests via biomarkers and transient elastography to assess NAFLD/NASH are being used in clinical practice. The most validated diagnostic panels include the NAFLD fibrosis score, FIB-4 (Fibrosis-4), and FibroMeter...
February 2018: Clinics in Liver Disease
https://www.readbyqxmd.com/read/29097288/trend-over-time-in-hepatic-fibrosis-score-in-a-cohort-of-type-2-diabetes-patients
#7
Carlo Bruno Giorda, Gabriele Forlani, Roberta Manti, Arianna Mazzotti, Salvatore De Cosmo, Maria Chiara Rossi, Antonio Nicolucci, Paolo Di Bartolo, Antonio Ceriello, Pietro Guida, Barbara Tartaglino, Giuseppina Russo
AIMS: The prevalence and progression of hepatic fibrosis and its correlated factors in type 2 diabetes (T2DM) are poorly known. We aimed to define the percentage of T2DM patients who progress to fibrosis and the factors associated with disease progression. METHODS: Data from the electronic health records of 1527 patients with diagnosed T2DM and nonalcoholic fatty liver disease (NAFLD), as diagnosed by the Fatty Liver Index, were extracted from the AMD Annals database, which collects data from the Italian network of diabetes clinics...
October 31, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29094442/prevalence-and-severity-of-non-alcoholic-fatty-liver-disease-are-underestimated-in-clinical-practice-impact-of-a-dedicated-screening-approach-at-a-large-university-teaching-hospital
#8
T Marjot, E Sbardella, A Moolla, J Hazlehurst, G D Tan, M Ainsworth, J F L Cobbold, J W Tomlinson
AIMS: To define the attitudes and current clinical practice of diabetes specialists with regard to non-alcoholic fatty liver disease and, based on the results, implement an evidenced-based pathway for non-alcoholic fatty liver disease assessment. METHODS: An online survey was disseminated to diabetes specialists. Based on findings from this survey, we sought a local solution by launching an awareness campaign and implementing a screening algorithm across all diabetes clinics at a secondary/tertiary referral centre...
November 2, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/29083080/underappreciation-of-non-alcoholic-fatty-liver-disease-by-primary-care-clinicians-limited-awareness-of-surrogate-markers-of-fibrosis
#9
Preya J Patel, Xuan Banh, Leigh U Horsfall, Kelly L Hayward, Fabrina Hossain, Tracey Johnson, Katherine A Stuart, Nigel N Brown, Nivene Saad, Andrew Clouston, Katharine M Irvine, Anthony W Russell, Patricia C Valery, Suzanne Williams, Elizabeth E Powell
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common cause of incidental liver test abnormalities. General practitioners have a key role in identifying people with NAFLD at risk of significant liver disease. Recent specialist guidelines emphasize the use of fibrosis algorithms or serum biomarkers rather than routine liver tests, to assess advanced fibrosis. This study evaluated primary care clinicians' current approach to diagnosis, management and referral of NAFLD. METHODS: A cross-sectional survey of primary care clinicians was undertaken through a structured questionnaire about NAFLD...
October 30, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/29082644/assessment-of-serum-golgi-protein-73-as-a-biomarker-for-the-diagnosis-of-significant-fibrosis-in-patients-with-chronic-hbv-infection
#10
Z Cao, Z Li, Y Wang, Y Liu, R Mo, P Ren, L Chen, J Lu, H Li, Y Zhuang, Y Liu, X Wang, G Zhao, W Tang, X Xiang, H Wang, W Cai, L Liu, C Zhu, S Bao, Q Xie
Transient elastography (TE) is accurate in staging fibrosis noninvasively. However, a reliable serum biomarker with comparable accuracy is also important, especially when TE is unreliable/unavailable. Therefore, we aimed to evaluate the diagnostic performance of serum Golgi protein 73 (GP73) for significant fibrosis in patients with chronic HBV infection. A total of 801 patients with chronic liver disease (CLD; 492 chronic HBV infection and 309 non-HBV liver disease) with liver biopsy performance were enrolled...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29077674/macrophage-activation-and-the-tumor-necrosis-factor-cascade-in-hepatitis-c-disease-progression-among-hiv-infected-women-participating-in-the-women-s-interagency-hiv-study
#11
Audrey L French, Jonathan W Martin, Charlesnika T Evans, Marion Peters, Seble G Kessaye, Marek Nowicki, Mark Kuniholm, Elizabeth Golub, Michael Augenbraun, Seema N Desai
BACKGROUND: HIV/hepatitis C-coinfected persons experience more rapid liver disease progression than hepatitis C virus (HCV) monoinfected persons, even in the setting of potent antiretroviral therapy. METHODS: We sought to articulate the role of macrophage activation and inflammation in liver disease progression by measuring serial soluble markers in HIV/HCV-coinfected women. We compared markers measured during retrospectively defined periods of rapid liver disease progression to periods where little or no liver disease progression occurred...
December 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29069995/pro-c3-a-new-and-more-precise-collagen-marker-for-liver-fibrosis-in-patients-with-chronic-hepatitis-c
#12
Janne Fuglsang Hansen, Mette Juul Nielsen, Kristina Nyström, Diana Julie Leeming, Martin Lagging, Gunnar Norkrans, Peer Brehm Christensen, Morten Karsdal
OBJECTIVE: Detecting significant fibrosis and cirrhosis remains important in treatment and follow-up of patients with chronic hepatitis C Infection (CHC). The aim of this study was to assess the ability of PRO-C3 to identify significant fibrosis (Ishak score ≥3) and cirrhosis (Ishak score ≥5) both as a single test and as a part of algorithms. MATERIALS AND METHODS: PRO-C3 was assessed in baseline samples from the NORDynamIC trial. 270 patients were stratified into groups according to baseline biopsy...
October 25, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29069254/accuracy-of-transient-elastography-fibroscan%C3%A2-acoustic-radiation-force-impulse-arfi-imaging-the-enhanced-liver-fibrosis-elf-test-apri-and-the-fib-4-index-compared-with-liver-biopsy-in-patients-with-chronic-hepatitis-c
#13
Taisa Grotta Ragazzo, Denise Paranagua-Vezozzo, Fabiana Roberto Lima, Daniel Ferraz de Campos Mazo, Mário Guimarães Pessoa, Claudia Pinto Oliveira, Venancio Avancini Ferreira Alves, Flair José Carrilho
OBJECTIVES: Although liver biopsy is the gold standard for determining the degree of liver fibrosis, issues regarding its invasiveness and the small amount of liver tissue evaluated can limit its applicability and interpretation in clinical practice. Non-invasive evaluation methods for liver fibrosis can address some of these limitations. The aim of this study was to evaluate the accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI), enhanced liver fibrosis (ELF), the aspartate aminotransferase-to-platelet ratio index (APRI), and the FIB-4 index compared with liver biopsy in hepatitis C...
October 2017: Clinics
https://www.readbyqxmd.com/read/29062242/impact-of-hepatitis-c-virus-genotype-4-eradication-following-direct-acting-antivirals-on-liver-stiffness-measurement
#14
Mohammed Tag-Adeen, Ahlam Mohamed Sabra, Yuko Akazawa, Ken Ohnita, Kazuhiko Nakao
BACKGROUND: Liver fibrosis is the most important prognostic factor in chronic hepatitis C virus (HCV) patients, and Egypt shows the highest worldwide HCV prevalence with genotype-4 pre-dominance. The aim of this study was to investigate the degree of liver stiffness measurement (LSM) improvement after successful HCV eradication. PATIENTS AND METHODS: The study included 84 chronic HCV Egyptian patients, and was conducted at Qena University Hospital from November 1, 2015 till October 31, 2016...
2017: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29040988/unique-characteristics-associated-with-sustained-liver-damage-in-chronic-hepatitis-c-patients-treated-with-direct-acting-antivirals
#15
Masashi Kono, Naoshi Nishida, Satoru Hagiwara, Tomohiro Minami, Hirokazu Chishina, Tadaaki Arizumi, Kosuke Minaga, Ken Kamata, Yoriaki Komeda, Toshiharu Sakurai, Mamoru Takenaka, Masahiro Takita, Norihisa Yada, Hiroshi Ida, Yasunori Minami, Kazuomi Ueshima, Tomohiro Watanabe, Masatoshi Kudo
BACKGROUND AND AIMS: Direct-acting antivirals (DAAs) dramatically improve the sustained virological response (SVR) of chronic hepatitis C (CHC) patients. However, continuous liver damage after SVR may be a risk of hepatocellular carcinoma (HCC). We clarified pretreatment characteristics related to sustained liver damage after SVR. METHODS: A total of 286 CHC patients were treated with an interferon-free DAA regimen. Among them, 250 patients achieved SVR for 12 weeks after the end of treatment (SVR12); these individuals were classified based on α-fetoprotein (AFP) and alanine transaminase (ALT) levels posttreatment...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/29040986/comparison-of-sofosbuvir-plus-ribavirin-treatment-with-pegylated-interferon-plus-ribavirin-treatment-for-chronic-hepatitis-c-genotype-2
#16
Kayo Seo, Soo Ki Kim, Soo Ryang Kim, Aya Ohtani, Mana Kobayashi, Airi Kato, Eri Morimoto, Yuka Saijo, Ke Ih Kim, Susumu Imoto, Chi Wan Kim, Yoshihiko Yano, Masatoshi Kudo, Yoshitake Hayashi
BACKGROUND: Sofosbuvir plus ribavirin (RBV) therapy showed higher sustained virological response at 12 weeks after treatment (SVR12) than pegylated interferon (peg-IFN) plus RBV; however, liver function, fibrosis, and hepatocellular carcinoma markers have not been assessed so far. SUMMARY: Patients (n = 21) receiving Sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV were enrolled in this study. Changes in alanine aminotransferase (ALT) and α-fetoprotein (AFP) levels, platelet (PLT) counts, FIB-4, and aspartate aminotransferase-to-platelet ratio index (APRI) in both groups were assessed in patients achieving SVR12...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/29040984/ability-of-cytokeratin-18-fragments-and-fib-4-index-to-diagnose-overall-and-mild-fibrosis-nonalcoholic-steatohepatitis-in-japanese-nonalcoholic-fatty-liver-disease-patients
#17
Natsuko Kobayashi, Takashi Kumada, Hidenori Toyoda, Toshifumi Tada, Takanori Ito, Masayoshi Kage, Takeshi Okanoue, Masatoshi Kudo
BACKGROUND: Several laboratory markers used in lieu of liver biopsy are reportedly useful in the diagnosis of nonalcoholic steatohepatitis (NASH). In the present study, we investigated the diagnostic impact of various non-invasive markers for predicting NASH. METHODS: A total of 229 nonalcoholic fatty liver disease (NAFLD) patients who underwent liver biopsy were enrolled for the study. The diagnostic ability of various markers to diagnose NASH from NAFLD was investigated...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/29028281/usefulness-of-the-index-of-nash-ion-for-the-diagnosis-of-steatohepatitis-in-patients-with-non-alcoholic-fatty-liver-an-external-validation-study
#18
Ramy Younes, Chiara Rosso, Salvatore Petta, Monica Cucco, Milena Marietti, Gian Paolo Caviglia, Alessia Ciancio, Maria Lorena Abate, Carlo Cammà, Antonina Smedile, Antonio Craxì, Giorgio Maria Saracco, Elisabetta Bugianesi
BACKGROUND & AIMS: The non-invasive identification of steatohepatitis (NASH) in patients with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non-invasive tools for fibrosis. METHODS: We analyzed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD...
October 13, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29020382/moderate-alcohol-use-is-not-associated-with-fibrosis-progression-in-hiv-hcv-co-infected-women-a-prospective-cohort-study
#19
Erin M Kelly, Jennifer L Dodge, Peter Bacchetti, Monika Sarkar, Audrey L French, Phyllis C Tien, Marshall J Glesby, Elizabeth T Golub, Michael Augenbraun, Michael Plankey, Marion G Peters
Background & Aims: Heavy alcohol use can lead to progressive liver damage, especially in individuals with chronic hepatitis C (HCV), however the impact of non-heavy use is not clear. We studied long-term effects of modest alcohol use on fibrosis progression in a large cohort of women co-infected with HIV/HCV. Methods: Alcohol intake was ascertained every 6 months and use categorized as abstinent, light (1-3 drinks/week), moderate (4-7 drinks/week), heavy (>7 drinks/week) and very heavy (>14 drinks/week)...
August 16, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29020239/reproductive-aging-and-hepatic-fibrosis-progression-in-hiv-hepatitis-c-virus-co-infected-women
#20
Monika Sarkar, Jennifer L Dodge, Ruth M Greenblatt, Mark H Kuniholm, Jack DeHovitz, Michael Plankey, Andrea Kovacs, Audrey L French, Eric C Seaberg, Igho Ofotokun, Margaret Fischl, Edgar Overton, Erin Kelly, Peter Bacchetti, Marion G Peters
Background: Severity of hepatic fibrosis is greater in post- as compared to pre-menopausal women, perhaps due to protective effects of estrogens. However, prior studies of estrogen and liver fibrosis lack serial fibrosis measures, adjustment for age, or longitudinal observations in co-infected populations. Methods: In a longitudinal cohort of HIV/HCV co-infected women we assessed fibrosis progression across reproductive age using validated serum fibrosis markers, APRI and FIB-4...
July 26, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
25413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"